Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Performance status

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7,655 result(s) found for: Performance status. Displaying page 1 of 383.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-005056-96 Sponsor Protocol Number: TRAWADA2015 Start Date*: 2016-05-31
    Sponsor Name:Daniel Sanabria Lucena
    Full Title: Use of tramadol in healthy volunteers. Effects on physical performance and sustained attention in cycling.
    Medical condition: Sport doping
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10076471 Drug doping LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-001639-38 Sponsor Protocol Number: GEMCAD-16-03 Start Date*: 2017-07-19
    Sponsor Name:Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD)
    Full Title: A phase II trial to evaluate the efficacy and safety of FOLFIRI + panitumumab as first-line treatment in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good ...
    Medical condition: First-line treatment in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good performance status
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-000617-43 Sponsor Protocol Number: CLEE011F2301 Start Date*: 2015-05-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: MONALEESA-3: A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor positive, HER2...
    Medical condition: men and postmenopausal women with HR+, HER2-negative advanced (loco regionally recurrent not amenable to curative therapy or metastatic) breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) AT (Completed) ES (Completed) CZ (Completed) DK (Completed) NL (Completed) HU (Completed) BE (Completed) BG (Completed) FR (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001216-19 Sponsor Protocol Number: Start Date*: 2014-11-13
    Sponsor Name:NHS Greater Glasgow & Clyde [...]
    1. NHS Greater Glasgow & Clyde
    2. University of Glasgow
    Full Title: Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose e...
    Medical condition: glioblastoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-002985-70 Sponsor Protocol Number: MD-R20080507 Start Date*: 2009-04-23
    Sponsor Name:University of Magdeburg
    Full Title: Evaluation of the preventive effect of pentoxifylline and ursodeoxycholic acid to radiation induced liver toxicity after brachytherapy of liver metastases, assessed in a prospective randomised trial.
    Medical condition: Irradiation damage to the liver after HDR-brachytherapy of liver metastases.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002637-11 Sponsor Protocol Number: CBYL719H12301 Start Date*: 2020-03-18
    Sponsor Name:Novartis Pharma AG
    Full Title: EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with adv...
    Medical condition: Advanced triple negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) SK (Completed) DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) NO (Completed) AT (Completed) BG (Completed) SI (Completed) PL (Completed) HR (Completed) GR (Completed) RO (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003084-61 Sponsor Protocol Number: CLEE011A2301 Start Date*: 2014-01-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast ...
    Medical condition: HR+, HER2- advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) DE (Completed) CZ (Completed) ES (Completed) SE (Completed) NL (Completed) HU (Completed) FI (Completed) IE (Completed) BE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003027-11 Sponsor Protocol Number: DURWIN Start Date*: 2019-05-16
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: A prospective, multi-center, open-label, single-arm, two- step phase II study of DURvalumab (MEDI4736) in patients WIth poor performance status as first-liNe treatment for advanced urothelial cance...
    Medical condition: Patients aged 18 years or older with histologically or cytologically documented locally advanced (on the TNM staging system, T4b and any N; or any T and N2–3) or metastatic (M1, stage IV) urothelia...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002794-35 Sponsor Protocol Number: CPDR001F2301 Start Date*: 2017-02-20
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated pati...
    Medical condition: Unresectable or metastatic BRAF V600 mutant melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) AT (Completed) CZ (Completed) PL (Completed) BG (Completed) GR (Completed) BE (Completed) PT (Completed) NL (Completed) DK (Completed) HU (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004059-22 Sponsor Protocol Number: CL3-95005-006 Start Date*: 2018-06-01
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of pati...
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) SE (Trial now transitioned) AT (Completed) ES (Ongoing) DK (Trial now transitioned) LT (Completed) NL (Completed) LV (Completed) SK (Trial now transitioned) CZ (Completed) HU (Completed) DE (Completed) PL (Trial now transitioned) PT (Completed) BG (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-009467-59 Sponsor Protocol Number: IJB-HIPEC-2009-01 Start Date*: 2010-03-18
    Sponsor Name:Institut Jules Bordet
    Full Title: Feasibility study of hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with stage III or only pleural stage IV ovarian carcinoma in first line therapy.
    Medical condition: Inclusion criteria : 1. Histologically confirmed ovarian carcinoma or primary peritoneal carcinoma or Fallopian tube carcinoma. 2. FIGO stage III disease or only pleural stage IV disease 3. Age les...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001966-39 Sponsor Protocol Number: CBYL719C2303 Start Date*: 2021-09-27
    Sponsor Name:Novartis Pharma AG
    Full Title: EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advan...
    Medical condition: Hormone receptor positive, HER2-negative advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002605-10 Sponsor Protocol Number: CJDQ443B12301 Start Date*: 2022-04-01
    Sponsor Name:Novartis Pharma AG
    Full Title: KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic K...
    Medical condition: Advanced non-small cell lung cancer harboring the KRAS G12C mutation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) HU (Trial now transitioned) ES (Ongoing) NO (Completed) GR (Trial now transitioned) PT (Trial now transitioned) FI (Trial now transitioned) DK (Completed) SI (Trial now transitioned) EE (Completed) IT (Trial now transitioned) PL (Completed) HR (Completed) IS (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004432-18 Sponsor Protocol Number: Caremore-Trastuzumab Start Date*: 2015-02-18
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: Activity of trastuzumab based chemotherapy in metastatic breast patients with HER2-negative primary tumor but HER2 positive circulating tumor cells (CareMore-Trastuzumab)
    Medical condition: Metastastic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003977-10 Sponsor Protocol Number: HNBE-03-02 Start Date*: 2004-11-12
    Sponsor Name:Genetronics Biomedical Corporation
    Full Title: A Randomized Trial Comparing Preservation of Function Status After Either MedPulser Electroporation With Intratumoral Bleomycin Therapy of Surgery in Patients With Locally Recurrent or Second Pri...
    Medical condition: Patients with locally recurrent or second primary SCC of the base tongue, posterior lateral pharyngeal wall, hypopharynx and larynx.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004485-21 Sponsor Protocol Number: HE9A/14 Start Date*: 2015-04-03
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: A study of cabazitaxel treatment in castration resistant bone metastatic prostate cancer patients evaluating the tumor microenvironment
    Medical condition: Castration resistant bone metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2004-002662-38 Sponsor Protocol Number: ZD1839IL/0704 Start Date*: 2004-11-12
    Sponsor Name:AstraZeneca AB
    Full Title: A PHASE III RANDOMISED, STRATIFIED, PARALLEL-GROUP, MULTI-CENTRE, COMPARATIVE STUDY OF ZD1839 (IRESSA®) 250 MG AND 500 MG VERSUS METHOTREXATE FOR PREVIOUSLY TREATED PATIENTS WITH SQUAMOUS CELL CARC...
    Medical condition: squamous cell carcinoma of the head and neck
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) LT (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004845-18 Sponsor Protocol Number: 1.4 Start Date*: 2019-03-27
    Sponsor Name:Lene Bæksgaard Jensen
    Full Title: LON-GAS TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without Bevacizumab in patients with platinum-refractory esophago-gastric adenocarcinoma. A randomized phase III study
    Medical condition: TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without bevacizumab in patients with platinum-refractory esophago-gastric adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-004107-37 Sponsor Protocol Number: HNBE-03-01 Start Date*: 2004-11-12
    Sponsor Name:Genetronics Biomedical Corporation
    Full Title: A Randomized Trial Comparing Preservation of Function Status After Either MedPulser® Electroporation with Intraumoral Bleomycin Therapy or Surgery in Patients with Locally Recurrent or Second Prima...
    Medical condition: Patients with locally recurrent or second primary SCC of the anterior oral cavity, soft palate, and tonsil that have failed primary curative therapy in whom surgical resection is seen as an option ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003406-40 Sponsor Protocol Number: RK2017 Start Date*: 2017-09-08
    Sponsor Name:Université catholique de Louvain
    Full Title: Repetitive blood donations and endurance sport performance: does iron supplementation limit the negative effects on hematological parameters?
    Medical condition: healthy subjects moderately active undergoing repeated blood donations
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 13:39:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA